Kevin Kunzmann

Updated analysis of more than a dozen clinical trials assessing monotherapy systemic treatment of atopic dermatitis shows upadacitinib's highly prevalent efficacy in clearing skin.

The long-acting injectable can be administered once every 2 months to either treat schizophrenia or serve as a maintenance monotherapy for bipolar disorder.

The research method, which provides better context into patient and caregiver perspective on the field, has increased nearly two-fold in prevalence since 2020.

A retrospective analysis shows patients unresponsive to either secukinumab, ixekizumab or brodalumab may benefit from another of them.

A California pilot program shows trained dogs may be able to sniff out COVID-19 with 90% specificity.

National data show mortality rates climbed 23% in 2020, primarily driven by increases among American Indian or Alaska Native people.

New research highlights the shared and unique characteristics of sleep and rest-activity rhythm measures among patients with schizophrenia.

A qualitative study shows nurses at an urban, academic emergency department vary on whether behavioral flagging results in safer patient interactions.

All but 5% of the state's inpatient beds are within 4 miles of an identified high fire-threat zone, according to new public health analyses.

New data suggest 10 years of consecutive poverty is a greater risk factor for death than dementia, obesity and stroke among Americans.

New CDC data show high-impact chronic pain has been decreasing since 2016, though the issue continues to disparately impact certain populations.

Black primary care physicians are now represented in more than 40% of US counties. A new study links the growth to improved Black individual health.

Countries including Taiwan have observed a reduced frequency or resumption of in-person phototherapy for chronic skin conditions due to the pandemic.

A questionnaire analysis from Germany shows patients are more likely to be satisfied with the safety and convenience of their topical drugs than they are their effectiveness in treating psoriasis.

On the latest Lungcast, Kalhan reviewed a 2018 paper he and colleagues penned on the need to establish phenotypes of chronic lung disease progression—such as what cardiology has done with LDL-C for heart attacks.

New survey data show patients with post-COVID-19 condition symptoms lasting more than 4 weeks are struggling to find caregivers and treatments relevant to their needs.

From a novel topical gene therapy to a multi-pathway targeting HF drug, the second quarter of 2023 is laden with interesting regulatory decisions.

April 7, 2023 marks the 75th anniversary of the WHO’s definition of health—a concept that experts point out is yet to be achieved, and faces many modern hurdles.

Data suggest confirmatory trials conducted for drugs granted accelerated approval by the FDA have taken a median 3.5 years to complete since 2012.

In the latest Lungcast, a pair of experts considered the marriage of low-dose CT scanning and machine learning to optimize lung disease interception.

The new recommendations buck against the organization's prior guidance, noting the variability of reported race and ethnicity that applies to clinical assessment.

As the US tries to move on from the pandemic, patients with long COVID-19 are fighting to regain normalcy while clinicians improve care plans and researchers search for answers.

The current pox virus outbreak has become closely synonymous with fewer lesions than past mpox—but dermatology guidance is needed all the same.

New phase 2b findings support the oral JAK1 inhibitor's capability to improve repigmentation versus placebo.

Symptoms including vestibular rashes and COVID toes have become less synonymous with SARS-CoV-2 infection. Why is that?

As the pandemic passes its third year, one dermatologist foresees their field's own pursuit of specialty-specific vaccination guidelines.

New phase 2b data show the oral PDE4 inhibitor could reduce psoriasis area severity by more than 60% in 16 weeks.

A small molecule IL-17A inhibitor, izokibep has additionally shown efficacy in treating psoriatic arthritis—and will now be reviewed in a phase 3 HS trial.

Pediatric dermatologist Mercedes Gonzalez, MD, discusses the new phase 3 B-SIMPLE data supporting berdazimer gel as the first potential molluscum treatment.

New phase 3 data from the BRAVE-AA trial program showed some patients who had little response to initial baricitinib achieved hair growth in year 2 of treatment.